MIRA Pharmaceuticals, Inc. (MIRA)

0.7380 +0.0279 (+3.93%) At close: 04:00PM EDT

MIRA Pharmaceuticals, Inc.

1200 Brickell Avenue
Suite 1950 #1183
Miami, FL 32183
United States
786-432-9792
https://mirapharmaceuticals.com

Sector(s): Healthcare
Industry: Drug Manufacturers - General
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Erez Aminov	CEO & Chairman	337.05k	N/A	1979
Ms. Michelle Yanez M.B.A.	CFO, Secretary & Treasurer	338.77k	N/A	1973
Dr. Itzchak Angel Ph.D.	Chief Scientific Advisor	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

Corporate Governance

MIRA Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.